Newron Pharmaceuticals Statistics
Total Valuation
FRA:NP5 has a market cap or net worth of EUR 230.85 million. The enterprise value is 240.21 million.
Market Cap | 230.85M |
Enterprise Value | 240.21M |
Important Dates
The last earnings date was Tuesday, September 16, 2025.
Earnings Date | Sep 16, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Current Share Class | 19.96M |
Shares Outstanding | n/a |
Shares Change (YoY) | +16.86% |
Shares Change (QoQ) | -11.63% |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | n/a |
Float | 18.88M |
Valuation Ratios
The trailing PE ratio is 9.11.
PE Ratio | 9.11 |
Forward PE | n/a |
PS Ratio | 3.86 |
PB Ratio | 145.93 |
P/TBV Ratio | 146.02 |
P/FCF Ratio | 9.41 |
P/OCF Ratio | 9.40 |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 6.80, with an EV/FCF ratio of 9.79.
EV / Earnings | 9.48 |
EV / Sales | 4.02 |
EV / EBITDA | 6.80 |
EV / EBIT | 6.84 |
EV / FCF | 9.79 |
Financial Position
The company has a current ratio of 1.51, with a Debt / Equity ratio of 33.23.
Current Ratio | 1.51 |
Quick Ratio | 1.40 |
Debt / Equity | 33.23 |
Debt / EBITDA | 1.49 |
Debt / FCF | 2.14 |
Interest Coverage | 8.00 |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | 50.97% |
Return on Invested Capital (ROIC) | 60.97% |
Return on Capital Employed (ROCE) | 165.16% |
Revenue Per Employee | 2.72M |
Profits Per Employee | 1.15M |
Employee Count | 22 |
Asset Turnover | 1.39 |
Inventory Turnover | n/a |
Taxes
In the past 12 months, FRA:NP5 has paid 5.55 million in taxes.
Income Tax | 5.55M |
Effective Tax Rate | 17.99% |
Stock Price Statistics
The stock price has increased by +39.01% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | +39.01% |
50-Day Moving Average | 8.70 |
200-Day Moving Average | 8.58 |
Relative Strength Index (RSI) | 63.06 |
Average Volume (20 Days) | 683 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, FRA:NP5 had revenue of EUR 59.88 million and earned 25.33 million in profits. Earnings per share was 1.19.
Revenue | 59.88M |
Gross Profit | 59.88M |
Operating Income | 35.20M |
Pretax Income | 30.88M |
Net Income | 25.33M |
EBITDA | 35.21M |
EBIT | 35.20M |
Earnings Per Share (EPS) | 1.19 |
Balance Sheet
The company has 43.20 million in cash and 52.57 million in debt, giving a net cash position of -9.37 million.
Cash & Cash Equivalents | 43.20M |
Total Debt | 52.57M |
Net Cash | -9.37M |
Net Cash Per Share | n/a |
Equity (Book Value) | 1.58M |
Book Value Per Share | 0.08 |
Working Capital | 20.39M |
Cash Flow
In the last 12 months, operating cash flow was 24.57 million and capital expenditures -37,000, giving a free cash flow of 24.53 million.
Operating Cash Flow | 24.57M |
Capital Expenditures | -37,000 |
Free Cash Flow | 24.53M |
FCF Per Share | n/a |
Margins
Gross margin is 100.00%, with operating and profit margins of 58.78% and 42.30%.
Gross Margin | 100.00% |
Operating Margin | 58.78% |
Pretax Margin | 51.57% |
Profit Margin | 42.30% |
EBITDA Margin | 58.81% |
EBIT Margin | 58.78% |
FCF Margin | 40.96% |
Dividends & Yields
FRA:NP5 does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -16.86% |
Shareholder Yield | n/a |
Earnings Yield | 10.97% |
FCF Yield | 10.63% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | |
Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
FRA:NP5 has an Altman Z-Score of 4.83 and a Piotroski F-Score of 5.
Altman Z-Score | 4.83 |
Piotroski F-Score | 5 |